Mr. Stephen Van Deventer reports

BIOGENE THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. BRIAN GALLAGHER, JR. TO CORPORATE ADVISORY BOARD

Preveceutical Medical Inc.'s wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Brian Gallagher Jr. to its corporate advisory board, effective Dec. 1, 2024.

Stephen Van Deventer, chief executive officer of BioGene, commented: "We are excited to welcome Dr. Brian Gallagher Jr. to our corporate advisory board. Brian's extensive leadership in venture capital, strategic investments and corporate development within the biotech and pharmaceutical sectors brings a wealth of expertise to BioGene. His proven track record in supporting innovative companies and driving them toward transformative success aligns perfectly with our vision of delivering groundbreaking therapies."

Dr. Gallagher's career highlights

Dr. Gallagher is a seasoned investor and entrepreneur with over 25 years of experience in biotech and pharmaceutical investments. He has held key leadership roles, including managing partner and co-founder of Trekk Venture Partners and partner at Abingworth, a transatlantic venture capital firm. Dr. Gallagher's expertise spans from overseeing investments in early-stage biotech companies to leading corporate development initiatives at Sirtris Pharmaceuticals, where he played a pivotal role in its $720-million acquisition by GlaxoSmithKline.

As a recognized leader in venture capital, Dr. Gallagher has guided companies from seed investment to public offerings, including serving as chairman of the board at eFFECTOR Therapeutics. His strategic insights have contributed to numerous high-profile exits, including Translate Bio's acquisition by Sanofi for $3.2-billion. Dr. Gallagher has also served on advisory boards at leading institutions, including the University of Michigan Biomedical Venture Fund and the National Brain Tumor Society.

Dr. Gallagher earned his PhD in organic chemistry from the University of Michigan and a BS in chemistry from the University of Massachusetts, Amherst. He is widely published in peer-reviewed journals and holds multiple patents related to drug development.

Dr. Gallagher remarked on his appointment: "I am honoured to join BioGene's corporate advisory board and contribute to the company's mission of advancing innovative therapies. BioGene's commitment to addressing critical unmet medical needs through cutting-edge science is truly inspiring. I look forward to supporting their strategic initiatives and growth trajectory."

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies, utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.